Anton P Porsteinsson1, Lea T Drye2, Bruce G Pollock3, D P Devanand4, Constantine Frangakis2, Zahinoor Ismail5, Christopher Marano6, Curtis L Meinert2, Jacobo E Mintzer7, Cynthia A Munro6, Gregory Pelton8, Peter V Rabins6, Paul B Rosenberg6, Lon S Schneider9, David M Shade2, Daniel Weintraub10, Jerome Yesavage11, Constantine G Lyketsos6. 1. University of Rochester School of Medicine and Dentistry, Rochester, New York. 2. Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 3. Campbell Institute, CAMH, University of Toronto, Toronto, Ontario, Canada. 4. Division of Geriatric Psychiatry, New York State Psychiatric Institute, New York5College of Physicians and Surgeons of Columbia University, New York, New York. 5. Departments of Psychiatry and Neurology, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada. 6. Johns Hopkins Bayview and Johns Hopkins School of Medicine, Baltimore, Maryland. 7. Clinical Biotechnology Research Institute, Roper St Francis Healthcare, Charleston, South Carolina. 8. Division of Geriatric Psychiatry, New York State Psychiatric Institute, New York. 9. University of Southern California Keck School of Medicine, Los Angeles. 10. Perelman School of Medicine at the University of Pennsylvania, Philadelphia. 11. Stanford University School of Medicine, Stanford, California12VA Palo Alto Health Care System, Stanford, California.
Abstract
IMPORTANCE: Agitation is common, persistent, and associated with adverse consequences for patients with Alzheimer disease. Pharmacological treatment options, including antipsychotics are not satisfactory. OBJECTIVE: The primary objective was to evaluate the efficacy of citalopram for agitation in patients with Alzheimer disease. Key secondary objectives examined effects of citalopram on function, caregiver distress, safety, cognitive safety, and tolerability. DESIGN, SETTING, AND PARTICIPANTS: The Citalopram for Agitation in Alzheimer Disease Study (CitAD) was a randomized, placebo-controlled, double-blind, parallel group trial that enrolled 186 patients with probable Alzheimer disease and clinically significant agitation from 8 academic centers in the United States and Canada from August 2009 to January 2013. INTERVENTIONS:Participants (n = 186) were randomized to receive a psychosocial intervention plus either citalopram (n = 94) or placebo (n = 92) for 9 weeks. Dosage began at 10 mg per day with planned titration to 30 mg per day over 3 weeks based on response and tolerability. MAIN OUTCOMES AND MEASURES: Primary outcome measures were based on scores from the 18-point Neurobehavioral Rating Scale agitation subscale (NBRS-A) and the modified Alzheimer Disease Cooperative Study-Clinical Global Impression of Change (mADCS-CGIC). Other outcomes were based on scores from the Cohen-Mansfield Agitation Inventory (CMAI) and the Neuropsychiatric Inventory (NPI), ability to complete activities of daily living (ADLs), caregiver distress, cognitive safety (based on scores from the 30-point Mini Mental State Examination [MMSE]), and adverse events. RESULTS: Participants who received citalopram showed significant improvement compared with those who received placebo on both primary outcome measures. The NBRS-A estimated treatment difference at week 9 (citalopram minus placebo) was -0.93 (95% CI, -1.80 to -0.06), P = .04. Results from the mADCS-CGIC showed 40% of citalopram participants having moderate or marked improvement from baseline compared with 26% of placebo recipients, with estimated treatment effect (odds ratio [OR] of being at or better than a given CGIC category) of 2.13 (95% CI, 1.23-3.69), P = .01. Participants who received citalopram showed significant improvement on the CMAI, total NPI, and caregiver distress scores but not on the NPI agitation subscale, ADLs, or in less use of rescue lorazepam. Worsening of cognition (-1.05 points; 95% CI, -1.97 to -0.13; P = .03) and QT interval prolongation (18.1 ms; 95% CI, 6.1-30.1; P = .01) were seen in the citalopram group. CONCLUSIONS AND RELEVANCE: Among patients with probable Alzheimer disease and agitation who were receivingpsychosocial intervention, the addition of citalopram compared with placebo significantly reduced agitation and caregiver distress; however, cognitive and cardiac adverse effects of citalopram may limit its practical application at the dosage of 30 mg per day. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00898807.
RCT Entities:
IMPORTANCE: Agitation is common, persistent, and associated with adverse consequences for patients with Alzheimer disease. Pharmacological treatment options, including antipsychotics are not satisfactory. OBJECTIVE: The primary objective was to evaluate the efficacy of citalopram for agitation in patients with Alzheimer disease. Key secondary objectives examined effects of citalopram on function, caregiver distress, safety, cognitive safety, and tolerability. DESIGN, SETTING, AND PARTICIPANTS: The Citalopram for Agitation in Alzheimer Disease Study (CitAD) was a randomized, placebo-controlled, double-blind, parallel group trial that enrolled 186 patients with probable Alzheimer disease and clinically significant agitation from 8 academic centers in the United States and Canada from August 2009 to January 2013. INTERVENTIONS:Participants (n = 186) were randomized to receive a psychosocial intervention plus either citalopram (n = 94) or placebo (n = 92) for 9 weeks. Dosage began at 10 mg per day with planned titration to 30 mg per day over 3 weeks based on response and tolerability. MAIN OUTCOMES AND MEASURES: Primary outcome measures were based on scores from the 18-point Neurobehavioral Rating Scale agitation subscale (NBRS-A) and the modified Alzheimer Disease Cooperative Study-Clinical Global Impression of Change (mADCS-CGIC). Other outcomes were based on scores from the Cohen-Mansfield Agitation Inventory (CMAI) and the Neuropsychiatric Inventory (NPI), ability to complete activities of daily living (ADLs), caregiver distress, cognitive safety (based on scores from the 30-point Mini Mental State Examination [MMSE]), and adverse events. RESULTS:Participants who received citalopram showed significant improvement compared with those who received placebo on both primary outcome measures. The NBRS-A estimated treatment difference at week 9 (citalopram minus placebo) was -0.93 (95% CI, -1.80 to -0.06), P = .04. Results from the mADCS-CGIC showed 40% of citalopramparticipants having moderate or marked improvement from baseline compared with 26% of placebo recipients, with estimated treatment effect (odds ratio [OR] of being at or better than a given CGIC category) of 2.13 (95% CI, 1.23-3.69), P = .01. Participants who received citalopram showed significant improvement on the CMAI, total NPI, and caregiver distress scores but not on the NPI agitation subscale, ADLs, or in less use of rescue lorazepam. Worsening of cognition (-1.05 points; 95% CI, -1.97 to -0.13; P = .03) and QT interval prolongation (18.1 ms; 95% CI, 6.1-30.1; P = .01) were seen in the citalopram group. CONCLUSIONS AND RELEVANCE: Among patients with probable Alzheimer disease and agitation who were receiving psychosocial intervention, the addition of citalopram compared with placebo significantly reduced agitation and caregiver distress; however, cognitive and cardiac adverse effects of citalopram may limit its practical application at the dosage of 30 mg per day. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00898807.
Authors: Lea T Drye; Zahinoor Ismail; Anton P Porsteinsson; Paul B Rosenberg; Daniel Weintraub; Christopher Marano; Gregory Pelton; Constantine Frangakis; Peter V Rabins; Cynthia A Munro; Curtis L Meinert; D P Devanand; Jerome Yesavage; Jacobo E Mintzer; Lon S Schneider; Bruce G Pollock; Constantine G Lyketsos Journal: Alzheimers Dement Date: 2012-02-01 Impact factor: 21.566
Authors: Robert Howard; Patrick Phillips; Tony Johnson; John O'Brien; Bart Sheehan; James Lindesay; Peter Bentham; Alistair Burns; Clive Ballard; Clive Holmes; Ian McKeith; Robert Barber; Tom Dening; Craig Ritchie; Rob Jones; Ashley Baldwin; Peter Passmore; David Findlay; Alan Hughes; Ajay Macharouthu; Sube Banerjee; Roy Jones; Martin Knapp; Richard G Brown; Robin Jacoby; Jessica Adams; Mary Griffin; Richard Gray Journal: Int J Geriatr Psychiatry Date: 2010-09-16 Impact factor: 3.485
Authors: Robert J Howard; Edmund Juszczak; Clive G Ballard; Peter Bentham; Richard G Brown; Roger Bullock; Alistair S Burns; Clive Holmes; Robin Jacoby; Tony Johnson; Martin Knapp; James Lindesay; John T O'Brien; Gordon Wilcock; Cornelius Katona; Roy W Jones; Julia DeCesare; Michaela Rodger Journal: N Engl J Med Date: 2007-10-04 Impact factor: 91.245
Authors: Clive G Ballard; Serge Gauthier; Jeffrey L Cummings; Henry Brodaty; George T Grossberg; Philippe Robert; Constantine G Lyketsos Journal: Nat Rev Neurol Date: 2009-05 Impact factor: 42.937
Authors: Michelle E Culang; Joel R Sneed; John G Keilp; Bret R Rutherford; Gregory H Pelton; D P Devanand; Steven P Roose Journal: Am J Geriatr Psychiatry Date: 2009-10 Impact factor: 4.105
Authors: Martin Steinberg; Huibo Shao; Peter Zandi; Constantine G Lyketsos; Kathleen A Welsh-Bohmer; Maria C Norton; John C S Breitner; David C Steffens; Joann T Tschanz Journal: Int J Geriatr Psychiatry Date: 2008-02 Impact factor: 3.485
Authors: Bruce G Pollock; Benoit H Mulsant; Jules Rosen; Sati Mazumdar; Richard E Blakesley; Patricia R Houck; Kimberly A Huber Journal: Am J Geriatr Psychiatry Date: 2007-09-10 Impact factor: 4.105
Authors: D P Devanand; Jesse G Strickler; Edward D Huey; Elizabeth Crocco; Brent P Forester; Mustafa M Husain; Ipsit V Vahia; Howard Andrews; Melanie M Wall; Gregory H Pelton Journal: Contemp Clin Trials Date: 2018-05-31 Impact factor: 2.226
Authors: Thitiporn Supasitthumrong; Blanca M Bolea-Alamanac; Selim Asmer; Vincent L Woo; Petal S Abdool; Simon J C Davies Journal: Br J Clin Pharmacol Date: 2019-02-08 Impact factor: 4.335
Authors: Laura N Gitlin; Katherine A Marx; Ian H Stanley; Bryan R Hansen; Kimberly S Van Haitsma Journal: Int Psychogeriatr Date: 2014-08-06 Impact factor: 3.878